Amyris has sold its Vitamin E royalty agreement to Koninklijke DSM N.V. for ~$57M, completing its exit from the business.
The parties have also agreed to cooperate further on the manufacture of Amyris products at DSM’s Brotas facility that Amyris says will generate another $30M – 40M in benefits over the next three years.
Shares are up 3% premarket on modest volume.
Date: April 29, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Seeking Alpha